Anthera Pharmaceuticals Company Profile (NASDAQ:ANTH)

About Anthera Pharmaceuticals

Anthera Pharmaceuticals logoAnthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ANTH
  • CUSIP:
Key Metrics:
  • Previous Close: $0.69
  • 50 Day Moving Average: $0.6224
  • 200 Day Moving Average: $2.0101
  • 52-Week Range: $0.51 - $4.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.54
  • P/E Growth: 0.0000
  • Market Cap: $29.13M
  • Outstanding Shares: 41,955,000
  • Beta: 1.16
Profitability:
  • Return on Equity: -202.44%
  • Return on Assets: -131.12%
Debt:
  • Current Ratio: 2.45%
  • Quick Ratio: 2.45%
Additional Links:
Companies Related to Anthera Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Anthera Pharmaceuticals (NASDAQ:ANTH) (?)
Ratings Breakdown: 4 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $1.59 (128.65% upside)

Analysts' Ratings History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Show:
DateFirmActionRatingPrice TargetDetails
12/29/2016Piper Jaffray CompaniesLower Price TargetOverweight$7.00 -> $1.35View Rating Details
12/29/2016Jefferies Group LLCDowngradeBuy -> Hold$5.00 -> $1.00View Rating Details
12/29/2016Citigroup Inc.DowngradeBuy -> NeutralView Rating Details
12/29/2016HC WainwrightReiterated RatingBuy$10.00 -> $3.00View Rating Details
12/28/2016SunTrust Banks, Inc.DowngradeBuy -> Hold$6.00 -> $1.00View Rating Details
6/20/2016FBR & CoReiterated RatingHoldView Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Anthera Pharmaceuticals (NASDAQ:ANTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/4/2016Q3($0.38)($0.61)ViewN/AView Earnings Details
8/9/2016Q2($0.31)($0.35)ViewN/AView Earnings Details
5/9/2016Q1($0.28)($0.29)ViewN/AView Earnings Details
3/10/2016Q4($0.27)($0.18)$1.92 millionViewN/AView Earnings Details
11/6/2015Q315($0.25)($0.29)ViewN/AView Earnings Details
8/10/2015Q2($0.28)($0.25)ViewN/AView Earnings Details
5/11/2015Q115($0.31)($0.28)ViewN/AView Earnings Details
3/16/2015($0.33)($0.32)ViewN/AView Earnings Details
11/14/2014($0.39)($0.31)ViewN/AView Earnings Details
7/28/2014($0.49)($0.34)ViewN/AView Earnings Details
5/13/2014Q114($0.46)($0.39)ViewN/AView Earnings Details
3/12/2014($0.47)($0.48)ViewN/AView Earnings Details
3/26/2013Q412($0.15)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Anthera Pharmaceuticals (NASDAQ:ANTH)
Current Year EPS Consensus Estimate: $-1.5900 EPS
Next Year EPS Consensus Estimate: $-1.2900 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.30)($0.30)($0.30)
Q2 20162($0.30)($0.29)($0.30)
Q3 20162($0.35)($0.33)($0.34)
Q4 20162($0.40)($0.31)($0.36)
Q1 20171($0.36)($0.36)($0.36)
Q2 20171($0.33)($0.33)($0.33)
Q3 20171($0.30)($0.30)($0.30)
Q4 20171($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Anthera Pharmaceuticals (NASDAQ:ANTH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Insider Ownership Percentage: 5.13%
Institutional Ownership Percentage: 50.87%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2015Colin HislopinsiderSell12,500$5.31$66,375.00View SEC Filing  
11/11/2015Colin HislopInsiderSell5,000$5.38$26,900.00View SEC Filing  
10/12/2015Debra OdinkCTOSell1,205$6.15$7,410.75View SEC Filing  
6/24/2013David E ThompsonDirectorBuy12,500$0.53$6,625.00View SEC Filing  
5/31/2013Bogdan DziurzynskiDirectorBuy1,250$0.59$737.50View SEC Filing  
1/30/2013Orbimed Advisors LlcDirectorBuy712,500$0.66$470,250.00View SEC Filing  
1/25/2013Orbimed Advisors LlcDirectorBuy220,250$0.65$143,162.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Anthera Pharmaceuticals (NASDAQ:ANTH)
DateHeadline
finance.yahoo.com logoIMPORTANT ANTHERA PHARMACEUTICALS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on (NASDAQ:ANTH)
finance.yahoo.com - February 24 at 8:47 PM
News IconStock Watch: Examining the Levels on Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Baldwin Journal (NASDAQ:ANTH)
baldwinjournal.com - February 24 at 3:46 PM
News IconThe Anthera Pharmaceuticals, Inc. (ANTH) Receives Consensus Recommendation of “Hold” from Brokerages - Petro Global News 24 (NASDAQ:ANTH)
petroglobalnews24.com - February 24 at 3:46 PM
News IconAnthera Pharmaceuticals, Inc. (ANTH) Price Target Cut to $1.35 by ... - Petro Global News 24 (NASDAQ:ANTH)
petroglobalnews24.com - February 24 at 12:08 PM
News IconAnalysts Peer Into Their Crystal Balls For Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH): Where Is It headed? - Winfield Review (NASDAQ:ANTH)
winfieldreview.com - February 23 at 3:35 PM
News IconAnthera Pharmaceuticals Inc (NASDAQ:ANTH): Ignore The Lawsuits - Insider Financial (NASDAQ:ANTH)
www.insiderfinancial.com - February 23 at 3:35 PM
4-traders.com logoOlympics, smartphones push Twitter revenue up 30 percent in Brazil (NASDAQ:ANTH)
www.4-traders.com - February 23 at 1:35 AM
News IconStockholder accuses pharmaceutical company, officers of fraud (NASDAQ:ANTH)
legalnewsline.com - February 23 at 1:35 AM
benzinga.com logoSHAREHOLDER ALERT: Brower Piven Notifies... (NASDAQ:ANTH)
www.benzinga.com - February 23 at 1:35 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Anthera Pharmaceuticals, Inc. (ANTH) To Contact Brower Piven Before The Lead Plaintiff (NASDAQ:ANTH)
finance.yahoo.com - February 23 at 1:35 AM
feeds.benzinga.com logoSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Anthera Pharmaceuticals, Inc. (ANTH) To Contact Brower Piven Before The Lead Plaintiff Deadline (NASDAQ:ANTH)
feeds.benzinga.com - February 22 at 11:57 PM
News IconSell-side Consensus Sees Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Going Where Near-Term? - Aiken Advocate (NASDAQ:ANTH)
aikenadvocate.com - February 22 at 8:33 PM
seekingalpha.com logoAnthera Pharmaceuticals Now Trading Below Cash Value. This ... - Seeking Alpha (NASDAQ:ANTH)
seekingalpha.com - February 22 at 3:33 PM
News IconANTH INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Anthera ... - EconoTimes (NASDAQ:ANTH)
www.econotimes.com - February 22 at 11:28 AM
globenewswire.com logoANTH INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Anthera ... - GlobeNewswire (press release) (NASDAQ:ANTH)
globenewswire.com - February 21 at 3:50 PM
News IconThe Technical Charts For Anthera Pharmaceuticals, Inc. (ANTH) Say It All Today - NY Stock News (NASDAQ:ANTH)
nystocknews.com - February 21 at 3:50 PM
feeds.benzinga.com logoANTH INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Anthera Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of April 17, 2017 (NASDAQ:ANTH)
feeds.benzinga.com - February 21 at 12:45 PM
News IconHemoglobinopathie Market: Global Industry Analysis And Opportunity And Forecast 2017 To 2022 (NASDAQ:ANTH)
www.free-press-release-center.info - February 20 at 3:29 PM
prnewswire.com logoJohnson & Weaver, LLP Announces Investigations of Clovis ... - PR Newswire (press release) (NASDAQ:ANTH)
www.prnewswire.com - February 19 at 7:45 AM
finance.yahoo.com logoJohnson & Weaver, LLP Announces Investigations of Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., and PixarBio Corporation (NASDAQ:ANTH)
finance.yahoo.com - February 19 at 7:45 AM
News IconAnthera Pharmaceuticals, Inc. (ANTH): The Technicals As Seen Today - NY Stock News (NASDAQ:ANTH)
nystocknews.com - February 18 at 3:31 PM
marketexclusive.com logoANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Notice of Delisting or Failure to Satisfy a ... - Market Exclusive (NASDAQ:ANTH)
marketexclusive.com - February 18 at 3:31 PM
businesswire.com logoRobbins Arroyo LLP: Anthera Pharmaceuticals, Inc. (ANTH) Misled Shareholders According to a Recently Filed Class ... - Business Wire (press release) (NASDAQ:ANTH)
www.businesswire.com - February 18 at 3:31 PM
4-traders.com logoOil prices slip as high stocks overshadow OPEC cuts (NASDAQ:ANTH)
www.4-traders.com - February 18 at 9:41 AM
einnews.com logoHemoglobinopathie Market to Reach $8.99 Billion with 10.0% CAGR Forecast to 2022 (NASDAQ:ANTH)
www.einnews.com - February 17 at 6:33 PM
finance.yahoo.com logoRobbins Arroyo LLP: Anthera Pharmaceuticals, Inc. (ANTH) Misled Shareholders According to a Recently Filed Class Action (NASDAQ:ANTH)
finance.yahoo.com - February 17 at 6:33 PM
biz.yahoo.com logoANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or (NASDAQ:ANTH)
biz.yahoo.com - February 16 at 8:40 PM
News IconLooking At Recent Analyst Recommendations: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), Prudential Financial ... - OracleTimes (NASDAQ:ANTH)
oracletimes.com - February 16 at 3:39 PM
News IconAnthera Pharmaceuticals, Inc. (ANTH): How technical indicators have come out? - Post Analyst (NASDAQ:ANTH)
postanalyst.com - February 16 at 3:39 PM
istreetwire.com logoMomentum Stocks: News Corporation (NWSA), Anthera Pharmaceuticals, Inc. (ANTH), Palatin Technologies, Inc. (PTN) - iStreetWire (NASDAQ:ANTH)
istreetwire.com - February 16 at 8:26 AM
News IconAre Analysts Optimistic About Where Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) is Heading? - Winfield Review (NASDAQ:ANTH)
winfieldreview.com - February 16 at 8:26 AM
feeds.benzinga.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Has Filed a Complaint to Recover Losses Suffered by Investors in Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)
feeds.benzinga.com - February 14 at 12:37 PM
thestreet.com logoTwitter, Coty, Micron Technology: Doug Kass' Views (NASDAQ:ANTH)
www.thestreet.com - February 13 at 1:34 AM
thestreet.com logoThese 5 Stocks Under $10 Could Explode Up Soon (NASDAQ:ANTH)
www.thestreet.com - February 9 at 3:36 PM
News IconVasculitis Market : New Tech Developments And Advancements To Watch Out For 2024!! (NASDAQ:ANTH)
www.medgadget.com - February 6 at 3:35 PM
prnewswire.com logoLifshitz & Miller LLP Announces Investigation of Anthera ... - PR Newswire (press release) (NASDAQ:ANTH)
www.prnewswire.com - February 3 at 8:43 PM
News IconSystemic Lupus Erythematous SLE Drugs Market Segments, Opportunity, Growth and Forecast By End-use Industry 2015-2025 (NASDAQ:ANTH)
www.medgadget.com - February 3 at 3:41 PM
News IconInherited Orphan Blood Disorders Therapeutics Market End-use Industry 2017-2027 (NASDAQ:ANTH)
reports.pr-inside.com - February 3 at 1:37 AM
News IconStock Tracker: Earnings & Estimates for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Aiken Advocate (NASDAQ:ANTH)
aikenadvocate.com - February 2 at 1:44 AM
News IconIs this Stock Under $5 a Bargain: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Prospect Journal (NASDAQ:ANTH)
prospectjournal.com - February 1 at 3:40 PM
News IconInvestors Swarm in on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Prospect Journal (NASDAQ:ANTH)
prospectjournal.com - January 31 at 8:45 PM
News IconCompetitive landscape: Vasculitis Market driven by rising incidences of metabolic disorders and circulatory disease (NASDAQ:ANTH)
www.medgadget.com - January 31 at 3:44 PM
openpr.com logoAnthera Pharmaceuticals Inc (NASDAQ:ANTH) Investor Investigation over possible Securities Laws Violations (NASDAQ:ANTH)
www.openpr.com - January 31 at 3:44 PM
News IconIs There Any Upside to This Stock Under $5: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Prospect Journal (NASDAQ:ANTH)
prospectjournal.com - January 31 at 2:42 AM
live-pr.com logoNew Report Available: Exocrine Pancreatic Insufficiency Global Clinical Trials Review, H2, 2016 (NASDAQ:ANTH)
www.live-pr.com - January 30 at 4:37 PM
News IconTaking a Look at the Chart for Anthera Pharmaceuticals, Inc. (ANTH) - The USA Commerce (NASDAQ:ANTH)
theusacommerce.com - January 27 at 4:21 PM
openpr.com logoWorldwide Vasculitis Market: North America is the leading region for the global vasculitis market owing to increasing healthcare awareness (NASDAQ:ANTH)
www.openpr.com - January 27 at 1:54 AM
News IconAnthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Upgrades/Downgrades Update - The Newburgh Press (NASDAQ:ANTH)
newburghpress.com - January 26 at 3:51 PM
News IconStock Update on Earnings & Estimates for Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Aiken Advocate (NASDAQ:ANTH)
aikenadvocate.com - January 26 at 1:43 AM
News IconHaemoglobinopathies Global Market, By Product & Data Validation, 2016 Analysis and Forecast 2022 (NASDAQ:ANTH)
www.emailwire.com - January 25 at 3:39 PM

Social

What is Anthera Pharmaceuticals' stock symbol?

Anthera Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANTH."

Where is Anthera Pharmaceuticals' stock going? Where will Anthera Pharmaceuticals' stock price be in 2017?

6 brokerages have issued 12 month price targets for Anthera Pharmaceuticals' shares. Their forecasts range from $1.00 to $3.00. On average, they anticipate Anthera Pharmaceuticals' share price to reach $1.59 in the next year.

When will Anthera Pharmaceuticals announce their earnings?

Anthera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

Who owns Anthera Pharmaceuticals stock?

Anthera Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (7.62%), FMR LLC (4.38%) and State Street Corp (1.63%). Company insiders that own Anthera Pharmaceuticals stock include Colin Hislop and Debra Odink.

Who sold Anthera Pharmaceuticals stock? Who is selling Anthera Pharmaceuticals stock?

Anthera Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and State Street Corp.

How do I buy Anthera Pharmaceuticals stock?

Shares of Anthera Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Anthera Pharmaceuticals stock cost?

One share of Anthera Pharmaceuticals stock can currently be purchased for approximately $0.69.

Anthera Pharmaceuticals (NASDAQ:ANTH) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Earnings History Chart

Earnings by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Dividend History Chart

Dividend Payments by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Last Updated on 2/25/2017 by MarketBeat.com Staff